(Q39241023)

10 September 2017

Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation (English)

1 reference

10 September 2017

Shyhmin Huang

1

1 reference

10 September 2017

Chunrong Li

2

1 reference

10 September 2017

Eric A Armstrong

3

1 reference

10 September 2017

Chimera R Peet

4

1 reference

10 September 2017

Jarob Saker

5

1 reference

10 September 2017

Lukas C Amler

6

1 reference

10 September 2017

Mark X Sliwkowski

7

1 reference

10 September 2017

Paul M Harari

8

1 reference

10 September 2017

language of work or name

English

0 references

publication date

20 November 2012

1 reference

10 September 2017

1 reference

10 September 2017

73

1 reference

10 September 2017

2

1 reference

10 September 2017

824-833

1 reference

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

10 September 2017

1 reference

12 December 2020

Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family

1 reference

12 December 2020

Awakening guardian angels: drugging the p53 pathway

1 reference

12 December 2020

HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation

1 reference

12 December 2020

Epidermal growth factor receptor targeting in cancer

1 reference

12 December 2020

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story

1 reference

12 December 2020

Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

1 reference

12 December 2020

Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells

1 reference

12 December 2020

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806.

1 reference

12 December 2020

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy

1 reference

12 December 2020

Oligomerization of the EGF receptor investigated by live cell fluorescence intensity distribution analysis

1 reference

12 December 2020

Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair.

1 reference

12 December 2020

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

1 reference

12 December 2020

Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.

1 reference

12 December 2020

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

1 reference

12 December 2020

A pan-HER approach for cancer therapy: background, current status and future development

1 reference

12 December 2020

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy

1 reference

12 December 2020

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

1 reference

12 December 2020

p53 modulates acquired resistance to EGFR inhibitors and radiation.

1 reference

12 December 2020

Spatial control of EGF receptor activation by reversible dimerization on living cells

1 reference

12 December 2020

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

12 December 2020

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

12 December 2020

Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity

1 reference

12 December 2020

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

1 reference

12 December 2020

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

1 reference

12 December 2020

A molecular link between AKT regulation and chemotherapeutic response.

1 reference

12 December 2020

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

12 December 2020

Biology of interactions: antiepidermal growth factor receptor agents

1 reference

12 December 2020

Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status

1 reference

12 December 2020

Characterization of a novel tripartite nuclear localization sequence in the EGFR family.

1 reference

12 December 2020

Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.

1 reference

12 December 2020

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

12 December 2020

Resistance to EGFR-targeted therapy: a family affair

1 reference

12 December 2020

10.1158/0008-5472.CAN-12-1611

Identifiers

DOI

1 reference

10 September 2017

1 reference